Gastric cancer immunotherapy

Clinical evaluation of immunogenic adjuvant therapy with dendritic cells loaded with autologous tumor mRNA in patients with gastric cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170208032451N1

Enrollment

Registered

2020-09-14

Start date

2021-01-20

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer. Malignant neoplasm of stomach

Interventions

Chimer Construction Design: using immunogenetic epitopes of MAGEA4, LAGE1, and NY-ESO1 antigens, a chimeric molecule is prepared which, due to the pivotal role of dendritic cells in inducing an immune

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with gastric adenocarcinoma whose histologically advanced malignancy (spread of cancer cells to lymph nodes and tumor metastasis) has been confirmed and they have filled out the informed consent form The patient must be over 18 years old at the time of diagnosis. Natural laboratory parameters, including these tests: Protein C& S, D-Dimer, VWF, CPK,LDH, TI, ALP, Lipase, Amylase, GGT, OB,CBC diff, Hgb electrophoresis, Serum Iron, Transferrin saturation, TIBC, CH50 (total complement), ESR, CRP, ACE, ANA, Anti CCP, RF, Auto antibodies, UA, Uric acid, Cr, Urea, SGPT, SGOT, Bilirubin, Albumin, Lipid profile, ACTH, Cortisol, FBS, HbA1c, OGT , ACTH, Cortisol, FBS, HbA1c, OGTT, Insulin, PTH, GH, Calcitonin, TFT, Testosterone, LH, FSH, Estrogen, Progestrone, PRL. To start immunotherapy, at least 4 weeks must have passed since the last course of chemotherapy or radiotherapy, and all the side effects of chemotherapy must be eliminated. Functional condition according to Karnowski criteria should be more than 60% Expected survival rate more than 6 months

Exclusion criteria

Exclusion criteria: brain metastasis autoimmune diseases Abnormal function of heart, liver, kidney, brain and other important organs

Design outcomes

Secondary

Measure	Time frame
Clinical and immune response. Timepoint: one year. Method of measurement: Flow cytometry - ELISA - Overall survival rate - Tumor-free survival rate.	—

Primary

Measure	Time frame
Side effect. Timepoint: 7 days. Method of measurement: clinical measurement.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Rbbaszadegan

Mashhad University of Medical Sciences

abbaszadeganmr@mums.ac.ir+98 51 3800 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026